Quick Facts

• Direct-to-consumer blood testing market will grow from $4.12 billion in 2026 to $8.16 billion by 2034
• Companies offer comprehensive testing for $99-$499, targeting health-conscious consumers frustrated with traditional healthcare
• Medical experts warn that 33% of test cascades start with clinically inappropriate initial tests

Companies like Oura and Function Health are capitalizing on Americans’ frustration with traditional healthcare by offering direct blood testing packages. But medical experts warn these convenient tests may create more problems than they solve.

The direct-to-consumer blood testing market is exploding. Projections show growth from $4.12 billion in 2026 to $8.16 billion by 2034. Blood-based tests represent 45% of the market, driven by consumers seeking proactive health management.

Major players are targeting existing customer bases. Oura sells blood test packages for $99 to its 5.5 million smart ring users. Function Health charges $365 annually for twice-yearly testing of 160 biomarkers. Hims & Hers offers similar services for $499, discounted to $349.

Function Health reports 40% of members come from ZIP codes with median household incomes below $95,000. This suggests the market extends beyond affluent biohackers into middle-class demographics.

Dr. Anna Wexler from the University of Pennsylvania explains the appeal: “There’s this idea that more information is better — that having access to information is empowerment. I think it comes completely as a response to frustration with the current state of our health care system.”

But medical professionals express serious concerns. Dr. Jeffrey Linder, chief of general internal medicine at Northwestern University, sees patients bringing self-ordered tests to appointments. “Patients are getting outside testing done and bringing them to appointments asking us to interpret them,” Linder said.

The biggest risk involves medical cascades. Abnormal results trigger additional testing, procedures, and anxiety. Linder warns: “You can even imagine a cascade where this leads to a bone marrow biopsy, something invasive and painful that has just a vanishingly small probability of turning up anything that is actually going to wind up improving your health.”

Research shows 33% of medical cascades begin with clinically inappropriate initial tests. Annual blood testing is not standard medical practice, according to Linder. “Everybody comes in and they’re like, ‘I want my routine blood work’ — and that’s not a thing,” he says.

The psychological impact concerns doctors too. “There’s this unrealistic expectation that the only two outcomes are you’re going to get a clean bill of health or you’re going to find something that’s going to kill you,” Linder explains. “It’s so much more likely that you’re going to find something indeterminate that’s going to cause anxiety.”

Companies defend their services as complementary to traditional care. Dr. Ricky Bloomfield, Oura’s chief medical officer, emphasizes: “It’s essential for people to have an ongoing relationship with a health care provider. Their blood test product is intended to complement — not replace — that relationship.”

Function Health’s co-founder Dr. Mark Hyman believes the testing catches early disease signs. The company has integrated with OpenAI’s ChatGPT Health to help users interpret results and track health trends over time.

The trend represents a fundamental shift in healthcare decision-making. Consumers are bypassing the traditional model where doctors determine testing needs and interpret results. Instead, they order tests independently and seek interpretation afterward.

Read more: You can order your own blood work now. Interpreting the results is another story